Business Context and Reporting Period
This Form 8-K is filed by Galena Biopharma, Inc. (noting a discrepancy in the request metadata which listed SELLAS Life Sciences Group, Inc.) for the reporting date of July 24, 2017. The filing addresses a binding settlement term sheet entered into to resolve a putative stockholder class action lawsuit pending in the Court of Chancery of the State of Delaware.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the settlement terms:
- Total Settlement Payment: $1.3 million
- Cash Component: $50,000 (to be paid by Defendants or insurers)
- Stock Component: $1.25 million in unrestricted common shares ("Settlement Stock")
- Attorney Fees: Amount to be approved by the Court; to be paid partially by the settlement fund and partially by insurance carriers.
Material Changes
The material change reported is the resolution of litigation captioned In re Galena Biopharma, Inc. The settlement resolves claims against the Company and certain current and former officers and directors, as well as the Company's petition to validate certain corporate actions. Upon effectiveness, Defendants will be released from claims asserted or that could have been asserted by participating class members.
Guidance, Outlook, and Risks
Management Commentary and Process: The settlement is contingent upon the negotiation of a Stipulation of Settlement and subsequent approval by the Court of Chancery of the State of Delaware. A hearing concerning the fairness of the terms will be held.
Risks and Contingencies: The issuance of the Settlement Stock is intended to be exempt from registration requirements under Section 3(a)(10) of the Securities Act. The settlement will not become effective until approved by the Court.
Investor Verification Checklist
- Verify the final approval of the Stipulation of Settlement by the Court of Chancery of the State of Delaware.
- Confirm the final valuation of the $1.25 million in Settlement Stock based on the volume-weighted average closing price of the 20 trading days preceding the transfer.
- Monitor the determination of attorney fees by the Court and the specific allocation of payment between the settlement fund and insurance carriers.
- Review the final terms of the release of claims for the Defendants.